Uncertainty related to the continued spread of the pandemic continued to consume most of the oxygen in the room this week, but life sciences news outside of that arena continued apace.
Once considered all but shuttered, the IPO market again saw... Read more »
The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on pharmaceutical products spanning the entire sector.
Royalty Pharma (NASDAQ: RPRX) acquires the royalty rights... Read more »
The FDA on Monday revoked its emergency authorization permitting use of the antimalarial drugs hydroxychloroquine and chloroquine to treat the novel coronavirus, citing a lack of evidence of their efficacy.
In late March the agency authorized the drugs, which President Donald... Read more »
At the start of 2020 thousands of biotechies anticipated spending the second week of June in San Diego, hobnobbing at the annual conference hosted by the Biotechnology Innovation Organization.
Instead, attendees from 64 countries spanning 28 times zones convened online this week... Read more »
Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test.
The study, set to begin next month, is targeting enrollment of about 30,000 volunteers,... Read more »
Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic disparities put some groups at higher risk than others. And yet clinical trials fail to reflect... Read more »
A year ago about 40,000 people gathered in Chicago for the annual meeting of the American Society of Clinical Oncology. Today a virtual version of the ASCO conference, the cancer field’s largest, kicks off, with oncologists and others tuning in from... Read more »
Xconomy Insight is excited to offer two special webinars to our community this June. Sponsored by Eurofins, registration is free to all.
Applying Cell-based In Vitro Assays to Improve In Vitro Hepatotoxicity Assessment Challenges
Date: Wednesday, June 10, 2020
... Read more »
COVID-19 has ravaged the economy, and it was expected to quash the IPO market, too. But the biotech sector is defying the pandemic with crossover financings and freshly minted public companies. On Friday, three firms added their names to the list... Read more »
As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine.
Moderna (NASDAQ: MRNA... Read more »
This was a disappointing week for at least two major drug makers. French firm Genfit reported a trial failure in an intensely competitive indication, and New York-based Bristol Myers Squibb encountered a delay when the FDA declined to review its experimental... Read more »
Alexion Pharmaceuticals CEO Ludwig Hantson has made no secret that he wants to diversify his company’s drug portfolio and he has shown willingness to open the corporate checkbook to accomplish that goal.
Last October, Alexion (NASDAQ: ALXN) struck a $930... Read more »
Chimeric antigen receptor T-cell therapies have shown remarkable efficacy in leukemia and lymphoma patients who relapsed or were refractory to several prior treatments, but many challenges remain in the cancer cell therapy field. Strategies that may improve upon first-generation therapies were... Read more »
Remdesivir, the investigational Gilead Sciences antiviral drug, looks more likely than ever to become the first treatment authorized by the FDA to treat patients with COVID-19.
National Institute of Allergy and Infectious Diseases (NIAID) head Anthony Fauci praised the drug after... Read more »
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing signs of slowing down, at least when it comes to drugs filed for accelerated approval. The... Read more »
The start of a potentially big biomedical breakthrough is blooming within all of us. Drug research aiming to turn bacteria into microbiome therapies now spans programs aiming to address gut disorders, autism, cancer, and more.
Given the number of late-stage and... Read more »
Two new special reports on Xconomy Insight provide an expert view on how companies can sustain clinical trials during the COVID-19 crisis. “Decentralized Clinical Trials: The Call for a New Paradigm” and “Sustaining Clinical Research During the Crisis... Read more »
The public markets are moving erratically, but Alnylam Pharmaceuticals showed this week that selling equity isn’t the only way for biotech companies to raise cash.
Late last year Alnylam (NASDAQ: ALNY) began exploring potential royalty deals for inclisiran, a drug... Read more »
[Updated, 3:13 p.m. See below.] Pharmaceutical giants GlaxoSmithKline and Sanofi are teaming up on COVID-19 research, aiming to combine their respective technologies in a new vaccine that could start clinical trials in coming months.
The full details of the... Read more »
The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences sector. The coronavirus research is expected. It’s the other activity that might come as a surprise.
Two... Read more »
Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech plan to start in coming weeks.
The partnership pairs the mRNA vaccine technology of BioNTech (NASDAQ: BNTX)... Read more »
Based on the latest news and analysis, as well as conversations from industry experts during the Combatting Coronavirus live panel at BIO-Europe Spring®, Xconomy’s free special report delivers the latest COVID-19 news from the frontlines as top biotech and investment players... Read more »
From Our Editors · Special Report
Learn what's fueling San Diego's biotech investment and partnership opportunities
Sponsored · Whitepaper
Leveraging technology & expertise to ensure a continual journey from trials to treatments
PRA Health Sciences
Sponsored · Whitepaper
Acknowledging various stakeholder networks and regulatory environment variances is essential to uncover the right decision-makers in support of biologics or biosimilars
IBM Watson
